Advice
In the absence of a submission from the holder of the marketing authorisation.
tolvaptan (Samsca®) is not recommended for use within NHSScotland for the treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice46KB (PDF)
Medicine details
- Medicine name:
- tolvaptan (Samsca)
- SMC ID:
- 605/10
- Indication:
- Adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH)
- Pharmaceutical company
- Otsuka Pharmaceutical Europe
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 18 January 2010